BioAge secures $90 million and prepares for clinical trials by 2021
BioAge labs, a biotech company focusing on longevity, is preparing for clinical trials following a $90 million Series C round of funding. The company announced that it would be moving BGE-117, BGE-175, and other platform-derived therapies into Phase 2 clinical studies in the first half 2021.
Longevity. We’ve been following developments at BioAge closely as the developers of an AI platform mapping the molecular pathway impacting human longevity. This company, which has two compounds that are ready to enter clinical trials next year and many more on the horizon, is one of the most promising prospects in the field of Longevity.
The funds will be used for BioAge to expand its AI platform and to enhance its ability to test drug candidate in predictive models to human diseases of ageing.
Source:
BioAge lands $90 million; gears up for clinical trials in 2021
